A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic uveal melanoma (MUM), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The pharmacokinetics (PK), preliminary anti-tumor activity, and potential biomarkers of VMD-102 will also be assessed. VMD-102 will be the first selective PKC epsilon (PKCε or PKCe) kinase inhibitor to enter human clinical testing. Preclinical VMD-102 anti-tumor activities in mouse liver/HCC tumor models and preclinical toxicology and pharmacology studies support this study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór (zaawansowany rak wątroby, melanoma, rak nerki, rak płuc lub jelita grubego), który nie reaguje na standardowe leczenie lub pacjent go nie toleruje
- •Ogólny stan zdrowia oceniany jako 0 lub 1 (pacjent aktywny, może wykonywać lekkie czynności)
- •Co najmniej jeden dostrzegalny guz do zmierzenia na obrazach medycznych
- •Hemoglobina co najmniej 9 g/dL
- •Liczba płytek krwi co najmniej 60 000/mm³
- •Liczba neutrofili co najmniej 1 500/mm³
- •Prawidłowa funkcja wątroby i nerek (билирубина do 2x normy, enzymy wątroby do 3-5x normy, klirens kreatyniny minimum 50 mL/min)
- •Prawidłowe parametry krzepnięcia krwi
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 19, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
HonorHealth Research Institute
Scottsdale, United States
Trial contact
Jay Wu, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/20/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.